Want to see CDNA full AI Analyst Report?
Revenue by Segment
Shows how the company’s sales break down across its different business lines (for example diagnostics, lab services, and recurring testing or monitoring). That split reveals which parts of the business are driving growth, which produce steadier, subscription-like income, and which are more exposed to reimbursement changes, competition, or single-customer concentration—key for judging future revenue stability and upside potential.Testing services have clearly become the growth and margin driver—recent quarters show accelerating volume and revenue-per-test gains—while Patient & Digital Solutions is a steadier, high‑growth second leg. Product/Lab revenues are small, volatile and declining, explaining management’s divestiture and cash‑return focus. Raised guidance and margin improvement lean on testing momentum and the Navaris acquisition to expand addressable markets, but watch revenue‑recognition timing noise and a modeled ~$7.5M LCD reimbursement headwind that could pressure near‑term per‑test economics and guidance execution.
Date | Product | Testing Services | Patient and Digital Solutions |
|---|---|---|---|
Jun 30, 2026 | $12.79M | $99.93M | $19.23M |
Mar 31, 2026 | $10.35M | $91.40M | $15.96M |
Dec 31, 2025 | $13.26M | $78.37M | $16.76M |
Sep 30, 2025 | $12.48M | $72.17M | $15.41M |
Jun 30, 2025 | $11.83M | $62.03M | $12.81M |
Mar 31, 2025 | $10.81M | $61.92M | $11.95M |
Dec 31, 2024 | $11.37M | $63.82M | $11.39M |
Sep 30, 2024 | $10.21M | $60.81M | $11.86M |
Jun 30, 2024 | $10.61M | $70.92M | $10.75M |
Mar 31, 2024 | $8.59M | $53.84M | $9.62M |